View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen announces issuance of €500 million inaugural Rated Public Bond Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well received and largely oversu...

 PRESS RELEASE

Ipsen annonce le succès de son émission obligataire inaugurale notée d...

Ipsen annonce le succès de son émission obligataire inaugurale notée d'un montant de 500 millions d'euros Cette transaction fait suite à l’attribution, par S&P et Moody’s, de notations de crédit ‘Investment Grade’ PARIS, FRANCE, 19 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui, le succès de son émission obligataire inaugurale notée de 500 millions d'euros, assortie d'un coupon de 3.875%, et arrivant à échéance en mars 2032. Cette transaction, lancée peu après l’attribution par S&P et Moody’s de notations de crédit ‘...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head o...

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025.  She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indications. Over the...

 PRESS RELEASE

Ipsen nomme Olivia Brown au poste de Vice-Présidente Exécutive, Direct...

Ipsen nomme Olivia Brown au poste de Vice-Présidente Exécutive, Directrice Mondiale des Neurotoxines PARIS, FRANCE, 12 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui la nomination d'Olivia Brown au poste de Vice-Présidente Exécutive, Directrice Mondiale des Neurotoxines, à compter du 1er avril 2025. Elle fera partie de l'équipe de direction d'Ipsen et sera directement rattachée au directeur général David Loew. Dans le cadre de ce poste nouvellement créé, elle dirigera la franchise mondiale des neurotoxines d'Ipsen, superv...

 PRESS RELEASE

Ipsen - February 2025 - Monthly information relative to the total numb...

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 28 February 2025 83,814,526 Gross t...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Ipsen : 2025: a year of operating margin consolidation

Given the modest clinical newsflow and expected operating margin decline in 2025 as well as the risk of a dilution of profitability relating to a possible late-stage deal, momentum and market timing on the stock are not ideal. Following the 2024 results and our road show, we maintain our Neutral rating, pending the period 2026-2027 which is likely to be more favourable than 2025.

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Ipsen : 2025 : année de consolidation de la marge opérationnelle

Compte tenu du newsflow clinique modeste et du tassement de MOP attendus pour 2025 ainsi que du risque de dilution de la profitabilité lié à un possible deal late stage, le couple momentum / market timing n’est pas idéal. A la suite des résultats 2024 et de notre roadshow, nous maintenons notre opinion Neutre, en attendant la période 2026-2027 qui devrait être plus favorable que l’année 2025.

 PRESS RELEASE

Ipsen S.A. publishes its 2024 consolidated financial statements

Ipsen S.A. publishes its 2024 consolidated financial statements Ipsen S.A. - 2024 Consolidated Financial Statements Attachment

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch